Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.
Overview
Atossa Therapeutics Inc (ATOS) is a clinical stage biopharmaceutical company that develops and markets innovative medicines, laboratory tests, and therapeutic delivery platforms focused on addressing unmet medical needs in oncology. With a primary emphasis on women’s breast health and breast cancer, the company is dedicated to advancing novel drug candidates and precision-targeted delivery systems, employing cutting-edge approaches such as selective estrogen receptor modulation and intraductal microcatheter technology.
Core Therapeutic Focus
The company’s flagship asset, (Z)-endoxifen, exemplifies its commitment to tackling critical challenges in breast cancer treatment. (Z)-endoxifen is a potent selective estrogen receptor modulator (SERM) that not only inhibits estrogen receptor activity but also facilitates its degradation. This dual action is strategically designed to address cases where resistance to traditional hormonal therapies exists, thus filling a significant therapeutic gap in oncology. Additionally, the formulation of (Z)-endoxifen is developed as an oral medication that bypasses the liver metabolism and gastric degradation issues, ensuring optimal bioavailability at therapeutic concentrations.
Innovative Drug Delivery Platforms
Beyond its core drug candidates, Atossa Therapeutics is also pioneering advanced delivery mechanisms to enhance therapeutic efficacy. The development of intraductal microcatheter technology represents a novel approach to deliver therapies directly to the site of breast cancer, thereby improving the targeting of treatments such as hormonal therapies, immunotherapies, and chimeric antigen receptor T-cell therapies. This targeted delivery strategy not only heightens the precision of treatment but also has the potential to reduce systemic side effects, contributing to an overall improved patient experience.
Clinical Development and Research Programs
Atossa’s development pipeline is robust, with multiple Phase 2 trials designed to evaluate the effectiveness of (Z)-endoxifen in diverse patient populations, including women with measurable breast density and those diagnosed with ductal carcinoma in situ. The company’s research initiatives extend to combination therapies, where (Z)-endoxifen is studied alongside other agents such as cyclin-dependent kinase (CDK) inhibitors, further broadening the therapeutic paradigm in breast cancer treatment. These programs underscore the company’s strategic emphasis on targeted oncology, employing rigorous clinical methods to substantiate the efficacy and safety of its novel therapies.
Intellectual Property and Market Position
Central to Atossa’s strategy is its strong intellectual property portfolio, which includes multiple issued U.S. patents and numerous pending applications. These patents cover both the composition of matter for (Z)-endoxifen and innovative formulation approaches, ensuring a competitive edge in the market. By protecting its technology and research investments, the company lays a solid foundation for long-term value creation, even as it navigates the challenges inherent to clinical stage development.
Competitive Landscape and Industry Expertise
Operating within the highly competitive biopharmaceutical industry, Atossa Therapeutics distinguishes itself through its integrated approach to drug development and delivery innovation. Its expertise in designing treatments that address both the efficacy and tolerability aspects of cancer care positions it uniquely among its peers. The company’s focus on precise molecular targeting and the development of therapeutics that are supported by robust scientific data bolsters its role as a knowledgeable and expertly positioned player in the oncology landscape.
Business Model and Operational Strategy
- Clinical Innovation: Concentrates on advancing clinical programs with a focus on unmet needs in breast cancer and breast health conditions.
- Targeted Delivery: Emphasizes pioneering approaches in delivering therapies directly to disease sites, using technologies like intraductal microcatheter systems.
- Intellectual Property: Leverages a strong portfolio of patents to secure its technological advancements and maintain market differentiation.
- Collaborative Research: Engages in strategic partnerships and clinical collaborations to enhance its research capabilities and validate its clinical hypotheses.
Conclusion
Atossa Therapeutics Inc exemplifies a focused, research-driven approach to addressing significant challenges in oncology. By combining novel therapeutic agents with innovative delivery systems, the company provides a comprehensive model for advancing personalized breast cancer treatment. Its commitment to enhancing patient outcomes through scientific rigor and technological innovation underscores its importance in the dynamic field of biopharmaceutical research. The detailed clinical programs, strategic intellectual property protections, and collaborative research efforts are all testaments to its expertise and nuanced understanding of complex oncology treatment paradigms.
Atossa Therapeutics (Nasdaq: ATOS) announced significant progress in 2022, focusing on its breast cancer program with the patented (Z)-endoxifen. Currently, Phase 2 studies are underway to prevent and treat breast cancer, particularly targeting ER+/HER2- patients. The FDA authorized the EVANGELINE study for neoadjuvant treatment, expecting to enroll 175 patients across 25 sites. The company reported a 65.1% reduction in Ki-67 levels from a prior study, suggesting improved outcomes. Atossa also invested $4.7 million in Dynamic Cell Therapies, enhancing its oncology portfolio. As of September 30, 2022, Atossa holds approximately $117 million in cash and equivalents, with no debt.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) has appointed Eric Van Zanten as Vice President of Investor and Public Relations. With over 25 years in corporate communications, particularly in biopharmaceuticals, Van Zanten will enhance the company's investor and public messaging. His previous roles include leadership positions at Faron Pharmaceuticals and Bristol-Myers Squibb. CEO Steven Quay expressed confidence in Van Zanten's ability to articulate Atossa's mission in oncology. Atossa focuses on innovative cancer treatments, specifically targeting breast cancer and lung injury from therapies.
Atossa Therapeutics (Nasdaq: ATOS) reported its financial results for Q3 2022, showing no revenue but a notable increase in operating expenses of 59% year-over-year, totaling $8,205, driven mainly by a 134% rise in R&D expenses. The company received FDA authorization for a Phase 2 study of (Z)-endoxifen for premenopausal women with ER+/HER2- breast cancer and is pursuing new immuno-oncology opportunities. As of September 30, 2022, Atossa had approximately $117,477 in cash. The total operating expenses for the first nine months of 2022 were $19,553, a 25% increase compared to 2021.
Atossa Therapeutics (Nasdaq: ATOS) announced its investment of $2 million in Dynamic Cell Therapies, acquiring a 19.99% stake. This move aligns with Atossa's strategy to explore CAR-T therapies in the immuno-oncology space, particularly for difficult-to-treat cancers. Previously, $3 million was invested in DCT, making a total of $5 million. The transaction is set to close in Q4 2022. DCT, based in Boston, is focused on developing controllable CAR-T therapies to enhance safety and efficacy in cancer treatments.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced the appointment of Dr. Richard Graydon as interim chief medical officer. Dr. Graydon, previously with Johnson & Johnson, brings extensive experience in CAR-T cell therapy and oncology drug development. He aims to enhance Atossa's clinical programs, including the Phase 2 oral Endoxifen program for breast cancer. Atossa focuses on innovative treatments for oncology, highlighting the need for effective cancer therapies.
Atossa Therapeutics has announced the initiation of a Phase 2 neoadjuvant study for its proprietary drug, (Z)-endoxifen, in premenopausal women with early-stage ER+/HER2- breast cancer. The U.S. FDA has lifted the clinical hold, allowing this key trial to move forward, which will involve about 175 patients across 25 sites. The study aims to determine whether (Z)-endoxifen is non-inferior to the standard treatment of exemestane + goserelin. Atossa has also decided to discontinue its COVID-19 program to focus on this significant research.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is set to participate in the 24th Annual H.C. Wainwright Global Investment Conference from September 12-14, 2022, at the Lotte New York Palace. Kyle Guse, General Counsel and CFO, will represent the company and is available for one-on-one meetings.
Atossa focuses on developing innovative therapies for unmet medical needs in oncology and infectious diseases, particularly in breast cancer and COVID-19.
For meeting requests and conference registration, visit here.
Atossa Therapeutics (Nasdaq: ATOS) will host a webinar on August 25, 2022, featuring CEO Dr. Steven Quay and CFO Kyle Guse. The event, starting at 8 AM Pacific, will discuss new opportunities for AT-H201, an inhalation therapy aimed at treating lung injuries from cancer treatments. Attendees can participate in a Q&A session regarding the company's research programs and future plans. Registration for the complimentary event is available online.
Atossa Therapeutics (Nasdaq: ATOS) announced the re-appointment of Drs. Mak Jawadekar, Per Hall, and Carl Novina to its Scientific Advisory Board (SAB) alongside the addition of Dr. Paul Wabnitz. The re-appointments are expected to strengthen Atossa's product development in oncology and infectious diseases, particularly in breast cancer and COVID-19. Dr. Wabnitz brings extensive clinical development experience, having worked on numerous oncology trials. This move aims to leverage their expertise to enhance Atossa's clinical programs and navigate challenges in drug development.
Atossa Therapeutics (Nasdaq: ATOS) reported its Q2 2022 financial results, highlighting key developments in their oncology and COVID-19 projects. The company completed dosing for AT-H201 in a Phase 1/2a trial aimed at hospitalized COVID-19 patients. Subsequently, they are shifting focus towards developing AT-H201 for cancer patients with lung damage from treatment. Financially, Atossa recorded operating expenses of $6,595, a 6% decrease from Q2 2021, with R&D expenses at $3,433, down 10%. Cash reserves stood at approximately $125,647, with no sustainable revenue reported.
FAQ
What is the current stock price of Atossa Therapeutics (ATOS)?
What is the market cap of Atossa Therapeutics (ATOS)?
What is the primary focus of Atossa Therapeutics Inc?
What is (Z)-endoxifen and why is it significant?
How does Atossa differentiate its drug delivery approach?
What stage is Atossa Therapeutics currently in?
How does the company strengthen its market position?
What are the core components of Atossa’s business model?
Who are the primary beneficiaries of Atossa’s therapies?
How does Atossa’s approach contribute to the field of oncology?
